SCHEMBL30102549

SCHEMBL30102549

O=C(O)c1cc(-c2ccc[nH]2)nc2ccccc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.63
LMNA P02545 2/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
PDE10A Q9Y233 1/20 0.63
DHODH Q02127 4/20 0.60
TACR3 P29371 1/20 0.60
NPC1 O15118 1/20 0.58
RAB9A P51151 1/20 0.58
AKR1C3 P42330 1/20 0.58
AKR1C2 P52895 1/20 0.58
AKR1C1 Q04828 1/20 0.58
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
POLB P06746 2/20 0.57
ALDH1A1 P00352 2/20 0.55
GLA P06280 2/20 0.55
GAA P10253 2/20 0.55
ESR1 P03372 1/20 0.55
TP53 P04637 1/20 0.55
HPGD P15428 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13957934 1.00 KDM4E (0.63) KDM4ELMNASMN1; SMN2PDE10ADHODH
SCHEMBL30604083 0.89 TACR3 (0.57) KDM4ELMNASMN1; SMN2PDE10ADHODH
SCHEMBL30604241 0.85 TACR3 (0.66) KDM4ELMNASMN1; SMN2DHODHTACR3
SCHEMBL29359819 0.82 KDM4E (0.83) KDM4ELMNASMN1; SMN2PDE10ADHODH
SCHEMBL18746 0.82 KDM4E (0.83) KDM4ELMNASMN1; SMN2PDE10ADHODH
SCHEMBL30595092 0.81 KDM4E (0.80) KDM4ELMNASMN1; SMN2PDE10ADHODH
SCHEMBL374558 0.81 KDM4E (0.80) KDM4ELMNASMN1; SMN2PDE10ADHODH
SCHEMBL374556 0.81 KDM4E (0.80) KDM4ELMNASMN1; SMN2PDE10ADHODH
Potassium SCHEMBL93448 0.81 KDM4E (0.80) KDM4ELMNASMN1; SMN2PDE10ADHODH
SCHEMBL7962360 0.81 KDM4E (0.80) KDM4ELMNASMN1; SMN2PDE10ADHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250074880-A1 NOVEL QUINOLINE DERIVATIVES AND USES THEREOF ST EUROPEO DI ONCOLOGIA S R L (IT) 2025-03-06 US disclosed
EP-4337640-A1 NOVEL QUINOLINE DERIVATIVES AND USES THEREOF Istituto Europeo di Oncologia S.r.l. (IT) 2024-03-20 EP disclosed
CN-116745291-A N- (2- (4-cyanothiazolidin-3-yl) -2-oxoethyl) -quinoline-4-carboxamide 阿斯利康(瑞典)有限公司 2023-09-12 CN disclosed
WO-2022238863-A1 NOVEL QUINOLINE DERIVATIVES AND USES THEREOF ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2022-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074880-A1 NOVEL QUINOLINE DERIVATIVES AND USES THEREOF NDC1, CHD1L, NUMA1 KDM4E 951/4885LMNA 907/4885SMN1; SMN2 2932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.